Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia Business Wire SAN DIEGO & WUHAN, China -- April 18, 2013 Illumina, Inc. (NASDAQ: ILMN) and Kindstar Global (Kindstar) today announced they are entering into a strategic collaboration whereby Kindstar will validate and implement molecular assays in their laboratories, leveraging Illumina’s TruSight^TM content sets, Infinium® Dx CytoSNP-12 assay and NuPCR^TM reagents. The collaboration will enable Kindstar to expand its esoteric and specialty testing services offerings within its network of more than 3,300 hospitals across China. “Kindstar’s adoption of Illumina’s TruSight technology across its extensive network in China speaks to the breadth and depth of content in this innovative portfolio,” said Matt Posard, Senior Vice President and General Manager of Illumina’s Translational and Consumer Genomics business. “Next-generation sequencing is enabling a dramatic improvement in both coverage and accuracy for molecular diagnostics, and we look forward to additional partnerships that continue to drive this improvement forward.” “Kindstar is excited to offer services in China based on Illumina’s products including the TruSight content sets,” said Dr. Shiang Huang, Founder and CEO of Kindstar. “Leveraging Illumina’s technology will enable us to offer the highest quality and most specialized diagnostics.” About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. About Kindstar Global Kindstar Global, with laboratory facilities inBeijing,ShanghaiandWuhan, provides esoteric diagnostic testing services to hospitals and physicians in every province ofChina. Kindstar is the first and largest esoteric diagnostic testing business inChina, providing laboratory testing services to over 3,300 Chinese hospitals, including 930 tertiary hospitals (classification for largest leading hospitals). Kindstar is becoming the partner of choice to physicians inChinafor advanced diagnostics in many medical specialties including hematology, oncology, infectious diseases and medical genetics. Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Contact: Illumina Inc. Investors: Rebecca Chambers 858-255-5243 firstname.lastname@example.org or Media: Jennifer Temple 858-882-6822 email@example.com
Illumina and Kindstar Global Announce Strategic Collaboration to Facilitate Clinical Adoption of Illumina Technologies in Asia
Press spacebar to pause and continue. Press esc to stop.